Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

@article{Kersemans2008DrugresistantAC,
  title={Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.},
  author={Veerle Kersemans and B. M. Cornelissen and Mark D Minden and Joseph E Brandwein and Raymond M Reilly},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2008},
  volume={49 9},
  pages={1546-54}
}
UNLABELLED Multidrug resistance (MDR) is a major challenge to the successful treatment of acute myeloid leukemia (AML). Our purpose was to determine whether (111)In-HuM195 anti-CD33 antibodies modified with peptides harboring nuclear localizing sequences (NLS) could kill drug-resistant AML cell lines and primary AML patient specimens expressing MDR transporters through the emission of Auger electrons. METHODS HuM195, M195, and irrelevant mouse IgG (mIgG) were conjugated to 10+/-3 NLS peptides… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…